[go: up one dir, main page]

DE102004059357B8 - Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung - Google Patents

Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung Download PDF

Info

Publication number
DE102004059357B8
DE102004059357B8 DE102004059357A DE102004059357A DE102004059357B8 DE 102004059357 B8 DE102004059357 B8 DE 102004059357B8 DE 102004059357 A DE102004059357 A DE 102004059357A DE 102004059357 A DE102004059357 A DE 102004059357A DE 102004059357 B8 DE102004059357 B8 DE 102004059357B8
Authority
DE
Germany
Prior art keywords
ligands
interaction
antibody blocking
human thy
thy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102004059357A
Other languages
English (en)
Other versions
DE102004059357A1 (de
DE102004059357B4 (de
Inventor
Anja Dr.rer.nat.habil. Saalbach
Anne Dipl.-Biol. Wetzel
Ulf Dr.rer.nat.habil. Anderegg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Leipzig
Original Assignee
Universitaet Leipzig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Leipzig filed Critical Universitaet Leipzig
Priority to DE102004059357A priority Critical patent/DE102004059357B8/de
Publication of DE102004059357A1 publication Critical patent/DE102004059357A1/de
Application granted granted Critical
Publication of DE102004059357B4 publication Critical patent/DE102004059357B4/de
Publication of DE102004059357B8 publication Critical patent/DE102004059357B8/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5751—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE102004059357A 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung Expired - Fee Related DE102004059357B8 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102004059357A DE102004059357B8 (de) 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004059357A DE102004059357B8 (de) 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

Publications (3)

Publication Number Publication Date
DE102004059357A1 DE102004059357A1 (de) 2006-06-14
DE102004059357B4 DE102004059357B4 (de) 2009-02-12
DE102004059357B8 true DE102004059357B8 (de) 2009-12-03

Family

ID=36500169

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004059357A Expired - Fee Related DE102004059357B8 (de) 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

Country Status (1)

Country Link
DE (1) DE102004059357B8 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
DE19944995C1 (de) * 1999-07-29 2000-12-21 Gsf Forschungszentrum Umwelt Nachweis einer irreversiblen Schädigung von IgG Antikörpern
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen
DE69828154T2 (de) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. Anti-alphavbeta3 humanizierte monoklonale antikörper

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
DE69828154T2 (de) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. Anti-alphavbeta3 humanizierte monoklonale antikörper
DE19944995C1 (de) * 1999-07-29 2000-12-21 Gsf Forschungszentrum Umwelt Nachweis einer irreversiblen Schädigung von IgG Antikörpern
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Anne Wetzel et al.,"Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)", Journal of Immunology (15. März 2004), Vol. 172, 3850-3859 *
CA AN 125:139735 *
Forschungsbericht der Univ. Leipzig 1999, Dr. Saalbach *
Forschungsbericht der Univ. Leipzig 2003, Dr. Saalbach *
Medline Abstr. AN 96021265 *
Medline Abstr. AN 96021265 CA AN 125:139735 Forschungsbericht der Univ. Leipzig 1999, Dr. Saalbach Forschungsbericht der Univ. Leipzig 2003, Dr. Saalbach Anne Wetzel et al.,"Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)", Journal of Immunology (15. März 2004), Vol. 172, 3850-3859

Also Published As

Publication number Publication date
DE102004059357A1 (de) 2006-06-14
DE102004059357B4 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE529420T1 (de) 3-ä(2-ää4-hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester-methansulfonat-hemihydrat und dessen verwendung als arzneimittel
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
IS8026A (is) Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun
ATE376357T1 (de) Chinolin-; isochinolin- und chinazolinoxyalkylamide und ihre verwendung als fungizide
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DE602006000339D1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
EP1940456A4 (de) Wwox-gen, vektoren damit und seine verwendung bei der krebsbehandlung
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE434608T1 (de) Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
DE602005006062D1 (de) Plättchenförmige Komposit-Partikeln und Kosmetika enthaltend die selben
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
DE60336025D1 (de) Kollimator und bestrahler

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8364 No opposition during term of opposition
8381 Inventor (new situation)

Inventor name: WETZEL, ANNE, DIPL.-BIOL., 04299 LEIPZIG, DE

Inventor name: ANDEREGG, ULF, DR.RER.NAT.HABIL., 04416 MARKKL, DE

Inventor name: SAALBACH, ANJA, DR.RER.NAT.HABIL., 04435 SCHKE, DE

8396 Reprint of erroneous front page
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20130702